CTLA4 and cancer: Immune checkpoint blockade (ICB) therapy targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) has garnered breakthrough therapeutic outcomes in the realm of cancer treatment1–4.